DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,050,343 B2 Peters Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,050,343 B2 Peters Et Al USOO9050343B2 (12) United States Patent (10) Patent No.: US 9,050,343 B2 Peters et al. (45) Date of Patent: Jun. 9, 2015 (54) COMBINATION OF PIMAVANSERIN AND 4,332,804 A 6, 1982 Clark RSPERIDONE FOR THE TREATMENT OF 13. A 9. at: al PSYCHOSIS 4,367,232 A 1/1983 Boix-Igleasias et al. (71) Applicants: Perry Peters, San Diego, CA (US); 3. A SME,R al David Furlano, San Diego, CA (US); 5,214,055 A 5/1993 Peglion et al. Daun Bahr, San Diego, CA (US); 5,216,165 A 6/1993 Mobilio et al. Daniel Van Kammen, San Diego, CA 5,461,066 A 10, 1995 Gericke et al. (US) 5,595,872 A 1/1997 Wetterau, II et al. 5,621,010 A 4/1997 Sueda et al. (72) Inventors: Perry Peters, San Diego, CA (US); 5,707,798 A 1/1998 Brann David Furlano, San Diego, CA (US); 3. A E. Shet al. Daun Bahr, San Diego, CA (US); 5,869,488 A 2, 1999 Shue et al. Daniel Van Kammen, San Diego, CA 5,877,173 A 3/1999 Olney et al. (US); Mark Brann, Rye, NH (US) 5,912,132 A 6/1999 Brann 5,955,281 A 9, 1999 Brann (73) Assignee: ACADIA Pharmaceuticals Inc., San 6,107,324 A 8, 2000 Behan et al. Diego, CA (US) 6,140,509 A 10/2000 Behan et al. 6,150,393 A 11/2000 Behan et al. (*) Notice: Subject to any disclaimer, the term of this E. R f29: y s al patent is extended or adjusted under 35 6,486,153- B1 1 1/2002 Castrooyes Pineiroet al. et al. U.S.C. 154(b) by 89 days. 6,670,137 B2 12/2003 VanMechelen et al. 6,756,393 B2 6/2004 Andersson et al. (21) Appl. No.: 13/754,769 6,815,458 B2 11/2004 Andersson et al. 6,911,452 B2 6/2005 Schlienger (22) Filed: Jan. 30, 2013 7,022,698 B2 4/2006 Hamied et al. 7,041,667 B1 5/2006 Armour et al. (65) Prior Publication Data 7,115,634 B2 10/2006 Thurieau et al. 7,253,186 B2 8/2007 Andersson et al. US 2013/0143901 A1 Jun. 6, 2013 7,601,740 B2 10/2009 Weiner et al. (Continued) Related U.S. Application Data (62) Division of application No. 12/051,807, filed on Mar. FOREIGN PATENT DOCUMENTS 19, 2008, now abandoned. CA 984843 3, 1976 (60) Provisional application No. 60/895,735, filed on Mar. EP 0 005 3.18 11, 1979 19, 2007, provisional application No. 60/908,921, (Continued) filed on Mar. 29, 2007, provisional application No. 61/012,771, filed on Dec. 10, 2007, provisional OTHER PUBLICATIONS application No. 61/026,092, filed on Feb. 4, 2008. Poewe (Movement Disorders vol. 18, Suppl. 6, 2003, pp.S80-S87).* (51) Int. Cl. (Continued) A 6LX3/59 (2006.01) A6 IK3I/4468 (2006.01) 3. f 3:08: Primary Examiner — David J Blanchard A6 IK3 L/455 (2006.01) Assistant Examiner — Garen Gotfredson A 6LX3/553 (2006.01) (74) Attorney, Agent, or Firm — Jones Day A6 IK3I/554 (2006.01) (52) U.S. Cl. CPC ............... A6 IK3I/519 (2013.01); A61 K3I/00 (57) ABSTRACT (2013.01); A61K3I/4468 (2013.01); A61 K 3 1/4515 (2013.01); A61 K3I/5513 (2013.01); Combinations of 5-HT2A inverse agonists or antagonists A61 K3I/554 (2013.01) Such as pimavanserin with antipsychotics Such as risperidone (58) Field of Classification Search are shown to induce a rapid onset of antipsychotic action and None increase the number of responders when compared to therapy See application file for complete search history. with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the inci (56) References Cited dence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose U.S. PATENT DOCUMENTS or prolactin levels caused by the antipsychotic. 3,983,234 A 9/1976 Sayers 4,138.492. A 2f1979 Noverola et al. 4.255.432 A 3/1981 Kluge et al. 6 Claims, 42 Drawing Sheets US 9,050,343 B2 Page 2 (56) References Cited WO WO 2005/053796 6, 2005 WO WO 2005/063254 7/2005 U.S. PATENT DOCUMENTS WO WO 2005/112927 12/2005 WO WO 2005.112927 A1 * 12/2005 7,659,285 B2 2/2010 Weiner et al. WO WO 2006/036874 4/2006 7,732.462 B2 6/2010 Weiner et al. WO WO 2006/037043 4/2006 7.994, 193 B2 8/2011 Weiner et al. WO WO 2006,104826 10, 2006 8.227.487 B2 7/2012 Weiner et al. WO WO 2004/039322 5/2007 8,377,959 B2 2/2013 Weiner et al. WO WO2007.1338O2 11, 2007 2002/0156068 A1 10, 2002 Behan et al. 2002fO165225 A1 11/2002 Kankan et al. OTHER PUBLICATIONS 2004.0006081 A1 1/2004 Burrows et al. 2004/0106600 A1 6/2004 Andersson et al. Adam, et al. 1989. Effects of repeated ritanserin on middle-aged poor 2004/021381.6 A1 10, 2004 Weiner et al. sleepers. Psychopharmacology, 99:219-221. 2005, OO14757 A1 1/2005 Andersson et al. Adell, et al. 2005. Strategies for producing faster acting antidepres 2005, 0148018 A1 7, 2005 Weiner et al. sants. Drug Discovery Today, 10(8):578-585. 2005/0244862 AI 1 1/2005 Brann Akin, et al. 2004. Decreased serotonin 5-HT, receptor-stimulated 2005/0256.108 Al 11/2005 Schlienger phosphoinositide signaling in fibroblasts from melancholic 28393. E. A. 39 Wine et al depressed patients. Neuropsychopharmacology, 29:2081-2087. 2005/0288328 A1 12, 2005 WE I. Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle 2006/0094758 A1 5/2006 Andersson et al dicloridrine e dalla tribromidrina della glicerina ordinaria, Gazz. 2006/0106063 A1 5/2006 Thhygesen et al. Chen. Ital. 22:158-168. 2006/011 1399 A1 5/2006 Thhygesen et al. Antilla, et al. 2001. Copper-catalyzed coupling of arylboronic acids 2006/O194778 A1 8/2006 Andersson et al. and amines. Organic Letters, 3(13):2077-2079. 2006, O194834 A1 8/2006 Andersson et al. Antilla, et al. 2002. The copper-catalyzed N-arylation of indoles. J. 2006/0199794 A1 9/2006 Schlienger Am. Chem. Soc., 124:1 1684-1 1688. 2006, O1998.18 A1 9/2006 Andersson et al. Antunes, et al., 2012. The novel object recognition memory: 2006, O199842 A1 9, 2006 Weiner et al. neurobiology, test procedure, and its modifications. Cogn Process 2006/0204486 A1 9/2006 Pyke et al. 13:93-110. 2006/0205710 A1 9/2006 Schlienger et al. Archibald, et al., 1974 “1,4-Bis-(2-indol-3-ylethyl)piperdines' J. 2006/0205722 A1 9/2006 Andersson et al. Medicinal Chemistry, 17(7):745-747. 2006/0205780 A1 9/2006 Thygesen et al. Archibald, et al., 1974 "Benzamidopiperdines. 2. Heterocyclic Com 2006/0205781 A1 9, 2006 Thvgesenyg et al. pounds Related to Indoramin' J. Medicinal Chemistry, 17(7):736 2006/0264465 A1 11/2006 Weiner et al. 739. 2006/0264466 A1 11/2006 Weiner et al. Archibald, et al., 1974 "Benzamidopiperdines. 3. Heterocyclic Com 2006/028661.0 A1 12, 2006 Brann pounds Related to Indoramin' J. Medicinal Chemistry, 17(7):739 2006,029.2606 A1 12, 2006 Brann 744. 2009.0053329 A1 2/2009 Peters et al. Artico, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. Eur: J. Med. Chem., 27:219-228. FOREIGN PATENT DOCUMENTS Bakshi, et al. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. The Journal of EP O 061333 9, 1982 Pharmacology and Experimental Therapeutics, 271 (2):787-794. EP O 379 441 7, 1990 Barchas, J. 1973. Serotonin and Behavior. New York: Academic EP O 548 O15 6, 1993 Press. EP O 260 070 8, 1993 Barnes, et al. 1999. A review of central 5-HT receptors and their FREP O28O2206 625 507 11,6, 20011994 function.inction. Neuropharmacology,N. h l 38:1083-115238:1U85-1154. HU 1573.25 3, 1998 Barr, et al. 1997. Agonist-independent activation of G by the JP 51052176 5, 1976 5-hydroxytryptamine receptor coexpressed in Spodoptera JP 52O8517 7/1977 frugiperda cells. The Journal of Biological Chemistry, WO WO 94,27967 12/1994 272(52):32979-32987. WO WO97,081.66 3, 1997 Bassus, et al. 1974. Psychotropes potentiels. X. Synthese de WO WO97,11940 4f1997 butyrophenones a cycle piperidine-spiro-tetrahydrooxazinone WO WO97/38665 10, 1997 douees d'activite neuroleptique. Eur: J. Med. Chem.–Chimica WO WO97,38984 10, 1997 Therapeutica, 9(4):416–423. WO WO98, 11128 3, 1998 Bennett, et al. 1993. Suppression of dyskinesias in advanced W. W. SE 38 Parkinson's disease. II. Increasing daily clozapine doses Suppress WO WO98,50534 11, 1998 dyskinesias and improve parkinsonism symptoms. Neurology, 43:1551-1555. W. W. 8587. 1992 Bhatia, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and struc WO WOOO,56335 9, 2000 ture-activity relationships of a series of 1-Aryl-2H4H-tetrahydro-1 WO WOOO. 59497 10, 2000 2,4-triazin-3-ones. J. Med. Chem. 39:3938-3950. WO WOOOf 69810 11, 2000 Biagi, et al. 1988. 1,2,3-Triazoles: Structural changes on two effec WO WOO1/44.191 6, 2001 tive inhibitors of the prostaglandin synthesis in vitro. Farmaco Ed. WO WOO1? 66521 9, 2001 Sci., 43:597-612. WO WOO1f87839 11, 2001 Bibbiani, et al. 2001. Serotonin 5-HT1A agonist improves motor W. w8%2: d29: complications in rodent and primate parkinsonian models.
Load more

Recommended publications
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N
    This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. Article Cite This: ACS Omega 2018, 3, 11163−11171 http://pubs.acs.org/journal/acsodf Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N. Lupas, Birte Hernandez Alvarez,* and Marcus D. Hartmann* Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany *S Supporting Information ABSTRACT: The protein cereblon serves as a substrate receptor of a ubiquitin ligase complex that can be tuned toward different target proteins by cereblon-binding agents. This approach to targeted protein degradation is exploited in different clinical settings and has sparked the development of a growing number of thalidomide derivatives. Here, we probe the chemical space of cereblon binding beyond such derivatives and work out a simple set of chemical requirements, delineating the metaclass of cereblon effectors. We report co-crystal structures for a diverse set of compounds, including commonly used pharmaceuticals, but also find that already minimalistic cereblon-binding moieties might exert teratogenic effects in zebrafish. Our results may guide the design of a post-thalidomide generation of therapeutic cereblon effectors and provide a framework for the circumvention of unintended cereblon binding by negative design
    [Show full text]
  • Ep 1553091 A1
    Europäisches Patentamt *EP001553091A1* (19) European Patent Office Office européen des brevets (11) EP 1 553 091 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C07D 263/32, C07D 417/14, 13.07.2005 Bulletin 2005/28 C07D 333/20, C07D 413/12, C07D 417/06 (21) Application number: 04726765.3 (86) International application number: (22) Date of filing: 09.04.2004 PCT/JP2004/005119 (87) International publication number: WO 2004/089918 (21.10.2004 Gazette 2004/43) (84) Designated Contracting States: • SAKAMOTO, Johei AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Takatsuki-shi, Osaka 569-1125 (JP) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • NAKANISHI, Hiroyuki Designated Extension States: Takatsuki-shi, Osaka 569-1125 (JP) AL HR LT LV MK • NAKAGAWA, Yuichi Takatsuki-shi, Osaka 569-1125 (JP) (30) Priority: 09.04.2003 JP 2003105267 • OHTA, Takeshi 03.06.2003 JP 2003157590 Takatsuki-shi, Osaka 569-1125 (JP) • SAKATA, Shohei (71) Applicant: Japan Tobacco Inc. Takatsuki-shi, Osaka 569-1125 (JP) Tokyo 105-8422 (JP) • MORINAGA, Hisayo Takatsuki-shi, Osaka 569-1125 (JP) (72) Inventors: • IKEMOTO, Tomoyuki (74) Representative: Takatsuki-shi, Osaka 569-1125 (JP) von Kreisler, Alek, Dipl.-Chem. et al • TANAKA, Masahiro Deichmannhaus am Dom, Takatsuki-shi, Osaka 569-1125 (JP) Postfach 10 22 41 • YUNO, Takeo 50462 Köln (DE) Takatsuki-shi, Osaka 569-1125 (JP) (54) HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF (57) A 5-membered heteroaromatic ring compound represented by the formula [I] 1 2 4 5 7 wherein V is CH or N; W is S or O; R and R are each H etc.; X is -N(R )-, -O-, -S-, -SO2-N(R )-, -CO-N(R )- etc.; L is EP 1 553 091 A1 Printed by Jouve, 75001 PARIS (FR) (Cont.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Fagin-Event-Laurahaas.Pdf
    Theory and Practice: Collaborating with Ron Fagin on Two Projects in Information Integration Laura Haas IBM Fellow and Director, IBM Research Accelerated Discovery Lab The Adventure Begins… 2 Heterogeneous Federation: Garlic Virtual, lazy integration Queries / Results Specified by queries Supports diverse data Query Processing Flexible; low upfront cost; downside may be poor performance Wrapper Wrapper Wrapper Wrapper database File Other systems Apps spreadsheets 3 Our first real applications were in life sciences (pharma) Queries / Results Query Processing Wrapper Wrapper Wrapper Wrapper Ketanserin, 74050-98-9, Ketanserina, Ketanserine, Ketanserinum, Ketanserin tartrate, Medline Perketal, Serefrex, Sufrexal, Taseron, NCBI literature C22H22FN3O3, CHEMBL51, R-41468, CHEBI:6123, R-41,468, Tocris-0908, 3-(2-(4-(4-Fluorobenzoyl)piperidin-1- Bio Assays Chem Compound yl)ethyl)quinazoline-2,4(1H,3H)-dione, Search AC1L1GSK, Spectrum2_001713, EINECS 277- 680-2, Biomol-NT_000096, UNII-97F9DE4CT4 The prototypical query for drug discovery: . “Find a compound with a structure like this one and assay results in this range” . Example: – Show me all the compounds similar to ketanserin that have been tested against members of the serotonin family and have an ic50 < 1E-8 with molecular weight between 375 and 450, and a logP value between 4 and 6 4 With Heterogeneous Sources, You Get Heterogeneous Semantics Lidanserin - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Lidanserin Ketanserin - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Ketanserin . Searching a database for compounds where “375 < Molwt < 450” yields a set Prazosin - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Prazosin Ambrisentan - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Ambrisentan Ambrisentin (378), Prazosin (383), Trimetaphen cansilate (365), Ketanserin (395) .
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • WHO Drug Information Vol. 03, No. 4, 1989
    WHO DRUG INFORMATION VOLUME 3 • NUMBER 4 • 1989 PROPOSED INN LIST 62 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA WHO Drug Information WHO Drug Information provides an cerned with the rational use of overview of topics relating to drug drugs. In effect, the journal seeks development and regulation that to relate regulatory activity to are of current relevance and im­ therapeutic practice. It also aims to portance, and will include the lists provide an open forum for debate. of proposed and recommended In­ Invited contributions will portray a ternational Nonproprietary Names variety of viewpoints on matters of for Pharmaceutical Substances general policy with the aim of (INN). Its contents reflect, but do stimulating discussion not only not present, WHO policies and ac­ in these columns but wherever tivities and they embrace socio­ relevant decisions on this subject economic as well as technical mat­ have to be taken. ters. WHO Drug Information is pub­ The objective is to bring issues that lished 4 times a year in English and are of primary concern to drug French. regulators and pharmaceutical manufacturers to the attention of a Annual subscription: Sw.fr. 50.— wide audience of health profes­ Airmail rate: Sw.fr. 60.— sionals and policy-makers con­ Price per copy: Sw.fr. 15.— © World Health Organization 1989 Authors alone are responsible for views expressed Publications of the World Health Organization in signed contributions. enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal The mention of specific companies or of certain Copyright Convention. For rights of reproduc­ manufacturers' products does not imply that they are tion or translation, in part or In toto, applica­ endorsed or recommended by the World Health tion should be made to: Chief, Office of Organization in preference to others of a similar na­ Publications, World Health Organization, ture which are not mentioned.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0053329 A1 Peters Et Al
    US 2009.0053329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0053329 A1 Peters et al. (43) Pub. Date: Feb. 26, 2009 (54) COMBINATIONS OF 5-HT2A INVERSE 61/012,771, filed on Dec. 10, 2007, provisional appli AGONSTS AND ANTAGONSTS WITH cation No. 61/026,092, filed on Feb. 4, 2008. ANTIPSYCHOTICS Publication Classification (75) Inventors: Perry Peters, San Diego, CA (US); (51) Int. Cl. David Furlano, San Diego, CA A633/00 (2006.01) (US); Daun Bahr, San Diego, CA A6II 3/445 (2006.01) (US); Daniel Van Kammen, San A 6LX 3/59 (2006.01) Diego, CA (US); Mark Brann, A6II 3/438 (2006.01) Rye, NH (US) A6IP 25/18 (2006.01) Correspondence Address: A 6LX 3L/2197 (2006.01) KNOBBE MARTENS OLSON & BEAR LLP A6II 3/54 (2006.01) 2040 MAINSTREET, FOURTEENTH FLOOR A6II 3/55 (2006.01) IRVINE, CA 92.614 (US) (52) U.S. Cl. .................... 424/722:514/329; 514/259.41: 514/278; 514/254.06; 514/222.2: 514/212.01 (73) Assignee: Acadia Pharmaceuticals, Inc., San Diego, CA (US) (57) ABSTRACT Combinations of 5-HT2A inverse agonists or antagonists (21) Appl. No.: 12/051,807 Such as pimavanserin with antipsychotics Such as risperidone are shown to induce a rapid onset of antipsychotic action and (22) Filed: Mar. 19, 2008 increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at Related U.S. Application Data a low dose of the antipsychotic, thereby reducing the inci (60) Provisional application No.
    [Show full text]